The company had earlier announced about the approval received from the MHRA for Liraglutide
First and only long-acting C5 complement inhibitor offers patients with AQP4 Ab+
The inspection at Unit 1 by the USFDA has been successfully completed, with no observations under Form 483
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
To accelerate the development of next-generation radioconjugates to treat cancer
Winlevi is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day
More than 10,000 scientific publications containing EUDRAGIT
Subscribe To Our Newsletter & Stay Updated